Trials / Recruiting
RecruitingNCT07258511
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti CD38 Antibody
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-79635322 | JNJ-79635322 will be administered as SC injection. |
| DRUG | Teclistamab | Teclistamab will be administered as SC injection. |
Timeline
- Start date
- 2026-02-04
- Primary completion
- 2028-12-12
- Completion
- 2031-09-30
- First posted
- 2025-12-02
- Last updated
- 2026-04-13
Locations
39 sites across 5 countries: United States, Australia, Brazil, Israel, Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07258511. Inclusion in this directory is not an endorsement.